This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
AACR 2020
Presentations

Tucatinib | Clinical Research | Abstract 3015/3
Tucatinib inhibits creatinine and metformin renal tubule secretion but has no effect on renal function (GFR)

Tucatinib | Preclinical Research | Abstract 4222/26
Tucatinib, a selective small molecule HER2 inibitor, is active in HER2 mutant driven tumors

Tucatinib | Clinical Research | Abstract 3016/4
Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers

Tucatinib | Preclinical Research | Abstract 1962/29
Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors

Enfortumab Vedotin | Urothelial Cancer | Abstract 5581/14
Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers

SEA-CD40 | Preclinical Research | Abstract 5535/25
SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors

SGN-B6A | Preclinical Research | Abstract 2906/23
SGN-B6A: A new MMAE ADC targeting integrin beta-6 in multiple carcinoma indications

SGN-CD30C | Preclinical Research | Abstract 2889/6
SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies

SGN-CD228A | Preclinical Research | Abstract 2888/5
Utilizing PDX models to better understand factors that predict response to SGN-CD228A, an antibody drug-conjugate (ADC) for solid tumors

Research | Preclinical Research | Abstract 2895/12
Characterization of payload release from a novel camptothecin drug-linker
Videos
SGN-CD30C | Preclinical Research | Abstract 2889/6
SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies
Tucatinib | Preclinical Research | Abstract 1962/29
Preclinical characterization of tucatinib in HER2-amplified xenograft and CNS implanted tumors
Tucatinib | Preclinical Research | Abstract 4222/26
Tucatinib, a selective small molecule HER2 inhibitor, is active in HER2 mutant driven tumors
Tucatinib | Clinical Research | Abstract 3015/3
Tucatinib inhibits creatinine and metformin renal tubule secretion but has no effect on renal function (GFR)
Tucatinib | Clinical Research | Abstract 3016/4
Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers